France Units July Deadline for Medical Hashish Rules as Withheld Research Exhibits Opioid Reductions

France’s well being minister has confirmed to Agence France-Presse (AFP) that the delayed regulatory texts wanted to push by means of its incoming generalised medical hashish market will likely be printed subsequent month (July 2026).

The dedication from French authorities follows the pressured launch of outcomes from France’s long-running medical hashish experiment, which confirmed that therapy was efficient in lowering opioid and analgesic use throughout 4 indications.

U.CANNABIS, which tracked practically 2000 sufferers earlier than and after receiving therapy, was accomplished in September 2025, however was by no means made accessible to the general public.

Now, due to a proper request to the Fee d’accès aux paperwork administratifs (CADA) by French hashish affiliation l’Union des industriels pour la valorisation des extraits de chanvre (UIVEC), the figures have been printed.

Ludovic Rachou, President of UIVEC, mentioned in a press launch to members: “The scientific knowledge is stacking up and converging. It’s French, it’s public, it’s strong. We’re asking the federal government to publish the texts earlier than the tip of June 2026. Sufferers in therapeutic deadlock have waited lengthy sufficient.”

France’s medical hashish limbo

France’s medical hashish pilot programme, launched in 2021, was initially supposed as a two-year proof of idea forward of a generalised nationwide framework. 5 years on, that framework has but to be enacted. Dogged by political inaction, the pilot has been repeatedly prolonged, with collaborating sufferers dropping from a peak of three,000 to round 700.

A extra steady political surroundings modified the calculus. The 2024 Social Safety Finance Act made generalisation a authorized obligation, and by early 2026 the ultimate regulatory steps had been in lastly movement.

At Hashish Europa Paris in February, officers from the Route Générale de la Santé and the Route de la Sécurité Sociale introduced the draft decree setting out how cannabis-based medicines can be evaluated and priced beneath France’s social safety framework.

That decree stays unpublished. Till it’s, HAS can’t ship a proper reimbursement opinion; with out that opinion, firms can’t register merchandise with ANSM, and generalised prescribing can’t start. July’s anticipated affirmation will mark the beginning of this closing course of.

U.CANNABIS Research

The publication of the information from the U.CANNABIS examine was a important consider securing a timeline dedication from the French well being minister. Solely after reviewing the outcomes was AFP prompted to hunt a direct response on when the rules can be printed.

Nonetheless, the discharge of the outcomes themselves can be a major improvement. The U.CANNABIS was commissioned instantly by ANSM, France’s medicines regulator, because the official scientific analysis of the nation’s medical hashish experimentation programme.

It was carried out independently by Inserm UMR 1219 and the AHeaD epidemiology crew on the Université de Bordeaux.

Researchers had been instructed to trace what occurred to sufferers’ healthcare consumption within the twelve months earlier than and the six months after they began medical hashish therapy.

In contrast to many real-world research, these weren’t self-reported outcomes, however had been based mostly on reimbursement knowledge. The analysis crew cross-referenced the ReCann scientific registry, which information each affected person enrolled within the experimentation, in opposition to the SNDS, France’s nationwide social safety reimbursement database.

The examine was finalised in September 2025, however remained sealed till UIVEC’s CADA request, 9 months later. Towards the present backdrop of delayed deliberations on how medical hashish ought to be reimbursed, figures monitoring sufferers’ interplay with healthcare extra broadly symbolize a important issue within the equasion.

What the examine discovered

The examine, seen by MEDCAN24, coated 1,971 sufferers throughout the 5 permitted indications. As an observational examine utilizing interrupted time sequence methodology, it could determine modifications in healthcare use related to hashish initiation, but it surely can’t precisely set up causation in the best way a randomised managed trial would.

Readers wishing to entry the complete doc ought to contact UIVEC instantly.

The authors concluded that medical hashish initiation reveals ‘a constructive influence, albeit of low depth, on healthcare use.’ The outcomes are statistically vital throughout most indications, however the impact sizes are modest.

U.CANNABIS examine: sufferers by indication

1,971 sufferers enrolled in France’s medical hashish experimentation, 2021–2023

Supply: U.CANNABIS examine (Inserm UMR 1219 / Université de Bordeaux), September 2025, seen by MEDCAN24

The clearest sign comes from refractory neuropathic ache, the biggest cohort at 1,105 sufferers. The share receiving analgesics fell by roughly 4 in each 100 after initiation, from round 73% to 69%.

Gabapentinoid use dropped by round three per 100, sturdy opioid use by 1.4 per 100, and benzodiazepine use by 1.6 per 100. Month-to-month attendances at specialist power ache day hospitals fell by round 0.9 per 100 monthly.

Palliative care reveals the biggest absolute numbers, with roughly 21 in each 100 sufferers fewer on sturdy opioids after initiation, and common each day opioid doses declining by 13.6 outlined each day doses per affected person.

Neuropathic ache: reductions throughout drug lessons and healthcare use

Discount per 100 sufferers after medical hashish initiation (n=1,105, all p<0.05)

* Month-to-month attendances at specialist power ache day hospitals, per 100 sufferers monthly.
All outcomes statistically vital (p≤0.04). Dose (DDD) knowledge not proven; gabapentinoid and total analgesic doses additionally declined considerably.

Supply: U.CANNABIS examine (Inserm UMR 1219 / Université de Bordeaux), September 2025, seen by MEDCAN24

The examine notes, nevertheless, that analgesic use on this group was already declining within the months earlier than medical hashish initiation, complicating direct attribution.

In oncology, round 12 in each 100 sufferers fewer obtained analgesics after initiation. Amongst sufferers with MS spasticity, the frequency of non-opioid analgesic use fell by about six in each 100, however the examine’s dose evaluation confirmed a rise in analgesic amount after initiation, a sample the authors attribute to modelling artefacts within the segmented regression reasonably than a real improve in medicine burden.

In refractory epilepsy, benzodiazepine reductions had been noticed however didn’t attain statistical significance, with the authors citing inadequate pattern dimension.

5 therapy traces, one drugs

Taken collectively, the neuropathic ache knowledge alone reveals reductions throughout 5 separate therapy traces, gabapentinoids, non-opioid analgesics, benzodiazepines, sturdy opioids, and specialist ache clinic visits.

For HAS, which should decide whether or not cannabis-based medicines displace present therapies or complement them, that could be a extra helpful sign than affected person self-report. The SNDS methodology, monitoring precise reimbursement claims, is the precise sort of proof the reimbursement analysis is designed to weigh.

The outcomes sit alongside a security document the reimbursement argument may even require. ANSM pharmacovigilance monitoring throughout the complete experimentation has recorded zero circumstances of dependancy or misuse. The latest monitoring interval logged 30 pharmacovigilance circumstances, eight severe, primarily neurological and psychiatric opposed occasions, and none involving dependency.

If the decree is printed on the brand new timeline, clears Conseil d’État evaluate, and HAS delivers its reimbursement opinion in autumn as anticipated, the primary prescriptions beneath the generalised framework are unlikely to return earlier than 2027.